Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Increases By 75.3%

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 4,750,000 shares, a growth of 75.3% from the January 31st total of 2,710,000 shares. Currently, 44.9% of the company’s stock are short sold. Based on an average daily trading volume, of 18,790,000 shares, the days-to-cover ratio is presently 0.3 days.

Hepion Pharmaceuticals Price Performance

Shares of NASDAQ HEPA traded down $0.02 during midday trading on Friday, hitting $0.13. 4,828,291 shares of the company’s stock were exchanged, compared to its average volume of 31,504,930. Hepion Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $3.33. The company has a market cap of $876,708.00, a PE ratio of -0.03 and a beta of 1.65. The firm’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.